Star Bulk Carriers Corp vs Viatris Inc — how do they compare? Star Bulk Carriers Corp trades at $31.1 (market cap $3.46B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Viatris Inc is far larger — about 5.5× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays the higher dividend (6.06%). Which is the better fit depends on your goals.
| SBLK | VTRS | |
|---|---|---|
Market Cap | $3.46B | $19.09B |
Sector | Industrials | Health |
52-Week High | $32.42 | $17.86 |
52-Week Low | $16.79 | $9.49 |
Enterprise Value | $4.14B | $31.21B |
Dividend Yield | 6.06% | 2.89% |
Signals from Pluang's Aura AI — not financial advice
Star Bulk Carriers (SBLK) trades at $31.02, down 4.32% on the day, with strong technical indicators showing a bullish trend. The company demonstrates robust fundamentals with Q2 2026 EPS of $1.21 beating expectations by 27%, maintaining a three-quarter earnings beat streak. Valuation metrics appear reasonable with P/E of 12.16 and P/B of 1.38, while profitability remains strong with 23.87% net income margin. Recent developments include a parallel listing on Euronext Athens and consistent dividend payments.
SBLK presents a compelling investment case with strong earnings momentum, attractive dividend yield, and positive analyst sentiment. However, risks include shipping rate volatility and geopolitical tensions affecting global trade. The stock's current technical strength and fundamental performance suggest potential upside, though investors should monitor industry cyclicality and the company's execution on its growth strategy.
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
Trailing returns across standard periods
Latest headlines on both assets
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →